Gene therapy of chronic inflammatory disease
Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is...
Gespeichert in:
| Veröffentlicht in: | Advanced drug delivery reviews 2000-11, Vol.44 (2), p.195-207 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 207 |
|---|---|
| container_issue | 2 |
| container_start_page | 195 |
| container_title | Advanced drug delivery reviews |
| container_volume | 44 |
| creator | Hedley, Mary Lynne |
| description | Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is changed and exposure to antigen is eliminated. The purpose of this review is to: (1) briefly outline common features of immune related inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allergic asthma; (2) provide a rationale for the development of gene based drugs for these indications; and (3) describe current experimental results that support the usefulness of this approach for creating novel DNA based therapeutics. |
| doi_str_mv | 10.1016/S0169-409X(00)00095-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72407604</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0169409X00000958</els_id><sourcerecordid>516550</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-607863b29301ae0adc3b6178b0390666a9ce92b0a076dfac3eafbc1f64f59e23</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlZ_grInUXB1kuwmm5NI0SoUPNiDt5DNTmiku1uTrdB_7_YDPfYyc3neeYeHkEsK9xSoePjoh0ozUJ83ALcAoPK0OCJDWkiWFkxlx2T4hwzIWYxfAJRJAadkQClIRmk-JHcTbDDp5hjMcp20LrHz0DbeJr5xC1PXpmvDOql8RBPxnJw4s4h4sd8jMnt5no1f0-n75G38NE1txniXCpCF4CVTHKhBMJXlpaCyKIErEEIYZVGxEgxIUTljORpXWupE5nKFjI_I9e7sMrTfK4ydrn20uFiYBttV1JJlfRKygyDn_QdU8oMgo1nOOYUezHegDW2MAZ1eBl-bsNYU9Ma73nrXG6kaQG-966LPXe0LVmWN1X9qL7oHHncA9t5-PAYdrcfGYuUD2k5XrT9Q8Qsbq5Dn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21453310</pqid></control><display><type>article</type><title>Gene therapy of chronic inflammatory disease</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Hedley, Mary Lynne</creator><creatorcontrib>Hedley, Mary Lynne</creatorcontrib><description>Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is changed and exposure to antigen is eliminated. The purpose of this review is to: (1) briefly outline common features of immune related inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allergic asthma; (2) provide a rationale for the development of gene based drugs for these indications; and (3) describe current experimental results that support the usefulness of this approach for creating novel DNA based therapeutics.</description><identifier>ISSN: 0169-409X</identifier><identifier>EISSN: 1872-8294</identifier><identifier>DOI: 10.1016/S0169-409X(00)00095-8</identifier><identifier>PMID: 11072115</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Allergies ; Arthritis, Rheumatoid - genetics ; Arthritis, Rheumatoid - immunology ; Arthritis, Rheumatoid - therapy ; Chronic Disease ; Chronic inflammatory disease ; Cytokines - genetics ; Cytokines - immunology ; Cytokines - therapeutic use ; Diseases ; DNA ; Gene therapy ; Genetic Therapy ; Humans ; Immunization ; Inflammatory Bowel Diseases - genetics ; Inflammatory Bowel Diseases - immunology ; Inflammatory Bowel Diseases - therapy ; Inflammatory response ; Multiple Sclerosis - genetics ; Multiple Sclerosis - immunology ; Multiple Sclerosis - therapy ; Patient treatment ; Receptors, Interleukin-1 - antagonists & inhibitors ; Th1 Cells - immunology ; Th2 Cells - immunology</subject><ispartof>Advanced drug delivery reviews, 2000-11, Vol.44 (2), p.195-207</ispartof><rights>2000 Elsevier Science B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-607863b29301ae0adc3b6178b0390666a9ce92b0a076dfac3eafbc1f64f59e23</citedby><cites>FETCH-LOGICAL-c423t-607863b29301ae0adc3b6178b0390666a9ce92b0a076dfac3eafbc1f64f59e23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0169409X00000958$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11072115$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hedley, Mary Lynne</creatorcontrib><title>Gene therapy of chronic inflammatory disease</title><title>Advanced drug delivery reviews</title><addtitle>Adv Drug Deliv Rev</addtitle><description>Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is changed and exposure to antigen is eliminated. The purpose of this review is to: (1) briefly outline common features of immune related inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allergic asthma; (2) provide a rationale for the development of gene based drugs for these indications; and (3) describe current experimental results that support the usefulness of this approach for creating novel DNA based therapeutics.</description><subject>Allergies</subject><subject>Arthritis, Rheumatoid - genetics</subject><subject>Arthritis, Rheumatoid - immunology</subject><subject>Arthritis, Rheumatoid - therapy</subject><subject>Chronic Disease</subject><subject>Chronic inflammatory disease</subject><subject>Cytokines - genetics</subject><subject>Cytokines - immunology</subject><subject>Cytokines - therapeutic use</subject><subject>Diseases</subject><subject>DNA</subject><subject>Gene therapy</subject><subject>Genetic Therapy</subject><subject>Humans</subject><subject>Immunization</subject><subject>Inflammatory Bowel Diseases - genetics</subject><subject>Inflammatory Bowel Diseases - immunology</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Inflammatory response</subject><subject>Multiple Sclerosis - genetics</subject><subject>Multiple Sclerosis - immunology</subject><subject>Multiple Sclerosis - therapy</subject><subject>Patient treatment</subject><subject>Receptors, Interleukin-1 - antagonists & inhibitors</subject><subject>Th1 Cells - immunology</subject><subject>Th2 Cells - immunology</subject><issn>0169-409X</issn><issn>1872-8294</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlZ_grInUXB1kuwmm5NI0SoUPNiDt5DNTmiku1uTrdB_7_YDPfYyc3neeYeHkEsK9xSoePjoh0ozUJ83ALcAoPK0OCJDWkiWFkxlx2T4hwzIWYxfAJRJAadkQClIRmk-JHcTbDDp5hjMcp20LrHz0DbeJr5xC1PXpmvDOql8RBPxnJw4s4h4sd8jMnt5no1f0-n75G38NE1txniXCpCF4CVTHKhBMJXlpaCyKIErEEIYZVGxEgxIUTljORpXWupE5nKFjI_I9e7sMrTfK4ydrn20uFiYBttV1JJlfRKygyDn_QdU8oMgo1nOOYUezHegDW2MAZ1eBl-bsNYU9Ma73nrXG6kaQG-966LPXe0LVmWN1X9qL7oHHncA9t5-PAYdrcfGYuUD2k5XrT9Q8Qsbq5Dn</recordid><startdate>20001115</startdate><enddate>20001115</enddate><creator>Hedley, Mary Lynne</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope><scope>7X8</scope></search><sort><creationdate>20001115</creationdate><title>Gene therapy of chronic inflammatory disease</title><author>Hedley, Mary Lynne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-607863b29301ae0adc3b6178b0390666a9ce92b0a076dfac3eafbc1f64f59e23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Allergies</topic><topic>Arthritis, Rheumatoid - genetics</topic><topic>Arthritis, Rheumatoid - immunology</topic><topic>Arthritis, Rheumatoid - therapy</topic><topic>Chronic Disease</topic><topic>Chronic inflammatory disease</topic><topic>Cytokines - genetics</topic><topic>Cytokines - immunology</topic><topic>Cytokines - therapeutic use</topic><topic>Diseases</topic><topic>DNA</topic><topic>Gene therapy</topic><topic>Genetic Therapy</topic><topic>Humans</topic><topic>Immunization</topic><topic>Inflammatory Bowel Diseases - genetics</topic><topic>Inflammatory Bowel Diseases - immunology</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Inflammatory response</topic><topic>Multiple Sclerosis - genetics</topic><topic>Multiple Sclerosis - immunology</topic><topic>Multiple Sclerosis - therapy</topic><topic>Patient treatment</topic><topic>Receptors, Interleukin-1 - antagonists & inhibitors</topic><topic>Th1 Cells - immunology</topic><topic>Th2 Cells - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hedley, Mary Lynne</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>MEDLINE - Academic</collection><jtitle>Advanced drug delivery reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hedley, Mary Lynne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene therapy of chronic inflammatory disease</atitle><jtitle>Advanced drug delivery reviews</jtitle><addtitle>Adv Drug Deliv Rev</addtitle><date>2000-11-15</date><risdate>2000</risdate><volume>44</volume><issue>2</issue><spage>195</spage><epage>207</epage><pages>195-207</pages><issn>0169-409X</issn><eissn>1872-8294</eissn><abstract>Immune mediated inflammation that culminates in severe tissue necrosis is the hallmark of diseases that result from an inappropriate response to antigen. The inflammatory response becomes chronic when antigen is non-limiting and persists until the reactive tissue is destroyed, or the environment is changed and exposure to antigen is eliminated. The purpose of this review is to: (1) briefly outline common features of immune related inflammatory diseases such as rheumatoid arthritis (RA), multiple sclerosis (MS), inflammatory bowel disease (IBD), and allergic asthma; (2) provide a rationale for the development of gene based drugs for these indications; and (3) describe current experimental results that support the usefulness of this approach for creating novel DNA based therapeutics.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>11072115</pmid><doi>10.1016/S0169-409X(00)00095-8</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0169-409X |
| ispartof | Advanced drug delivery reviews, 2000-11, Vol.44 (2), p.195-207 |
| issn | 0169-409X 1872-8294 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72407604 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Allergies Arthritis, Rheumatoid - genetics Arthritis, Rheumatoid - immunology Arthritis, Rheumatoid - therapy Chronic Disease Chronic inflammatory disease Cytokines - genetics Cytokines - immunology Cytokines - therapeutic use Diseases DNA Gene therapy Genetic Therapy Humans Immunization Inflammatory Bowel Diseases - genetics Inflammatory Bowel Diseases - immunology Inflammatory Bowel Diseases - therapy Inflammatory response Multiple Sclerosis - genetics Multiple Sclerosis - immunology Multiple Sclerosis - therapy Patient treatment Receptors, Interleukin-1 - antagonists & inhibitors Th1 Cells - immunology Th2 Cells - immunology |
| title | Gene therapy of chronic inflammatory disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A07%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20therapy%20of%20chronic%20inflammatory%20disease&rft.jtitle=Advanced%20drug%20delivery%20reviews&rft.au=Hedley,%20Mary%20Lynne&rft.date=2000-11-15&rft.volume=44&rft.issue=2&rft.spage=195&rft.epage=207&rft.pages=195-207&rft.issn=0169-409X&rft.eissn=1872-8294&rft_id=info:doi/10.1016/S0169-409X(00)00095-8&rft_dat=%3Cproquest_cross%3E516550%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21453310&rft_id=info:pmid/11072115&rft_els_id=S0169409X00000958&rfr_iscdi=true |